The high cardiovascular risk of HIV infected (HIV þ ) patients is still partly unexplained. We aimed to evaluate if HIV infection and highly active antiretroviral therapy (HAART) are linked per se to left ventricular (LV) remodelling, independently of blood pressure (BP) values. We enrolled 4 groups of patients matched by gender, age, body mass index and smoking habit: 30 HIV þ hypertensives, 30 HIV þ normotensives, 30 notinfected (HIVÀ) hypertensives and 30 HIVÀ normotensives. HIV þ patients were on chronic HAART. Hypertension was newly diagnosed (p6 months) and never treated. Each patient underwent blood tests, 24-h BP monitoring and LV echocardiogram. The 4 groups had similar fasting glucose and cholesterol; triglycerides, HOMA index and prevalence of metabolic syndrome were higher in the HIV þ groups. Despite similar 24-h BP values, HIV þ hypertensives had greater LV mass and higher prevalence of preclinical diastolic dysfunction than HIVÀ hypertensives. Compared to HIVÀ normotensives, HIV þ normotensives had similar 24-h BP values, but greater LV mass and lower LV diastolic indices, similar to HIVÀ hypertensives, whose 24-h BP values were higher. Asymptomatic HIV infection and chronic HAART are associated with myocardial hypertrophy and preclinical diastolic dysfunction, independently of BP values.
Introduction
The introduction of highly active antiretroviral therapy (HAART) significantly changed the course of human immunodeficiency virus (HIV) infection, with a great extension of life expectancy and an increased incidence of cardiovascular events, not only related to age.
1,2 HIV infected (HIV þ ) subjects share many risk factors with the general population, including the highly prevalent smoking habit, but HIV infection itself and chronic HAART may contribute to the higher cardiovascular risk with mechanisms still partly unexplained. [3] [4] [5] Among the traditional cardiovascular risk factors, arterial hypertension in HIV þ patients has a prevalence similar or slightly higher than in the general population. 6, 7 Beside its role as a powerful risk factor in itself, hypertension entails left ventricular (LV) changes, mainly characterized by myocardial hypertrophy and diastolic dysfunction, that are per se independent predictors of cardiovascular events. 8, 9 HIV infection and HAART may cause blood pressure (BP) elevation, 7, 10 but could play a role in the development of LV remodelling, also independently of BP values. In fact HIV þ patients develop a wide range of metabolic and anthropometric abnormalities, including insulin resistance, diabetes, hypertrygliceridemia and increased abdominal adiposity. 3, 4, 11 Some of these abnormalities, such as visceral obesity and insulin resistance, have been linked per se to myocardial hypertrophy and diastolic dysfunction; moreover all these pathologic changes, together with hypertension, are components of the metabolic syndrome that has been associated with LV remodelling in subjects without HIV infection.
Previous studies [17] [18] [19] [20] [21] [22] [23] [24] on LV characteristics in HIV þ patients reached dissimilar results, probably because of great differences in study design, methods and patients characteristics.
Moving from these considerations, we designed a prospective study to evaluate if HIV infection and chronic HAART are linked to LV remodelling per se, independently of BP values.
Methods

Patients
The HIV þ patients were consecutively enrolled among the subjects referred to our outpatients' clinic for Infectious Diseases, using the following criteria: asymptomatic HIV infection, stable HAART during 12 months before the enrolment, normal BP (at enrolment 24-h BP o125/80 mm Hg) or recently (p6 months) diagnosed arterial hypertension (at enrolment 24-h BP X130 and/or 85 mm Hg), LV echocardiogram of good quality, no previous or current treatment with antihypertensive drugs or statins, no clinical, electrocardiographic or echocardiographic evidence of heart failure, myocardial infarction, angina pectoris, congenital or valvular heart diseases; no systemic diseases, such as diabetes mellitus or connective tissue disorders, able per se to influence LV morpho-functional characteristics; no severe liver or renal failure; no ethanol abuse or active drug use.
Following these criteria, from 800 patients evaluated during 18 months, we enrolled 30 HIV þ hypertensives and 30 HIV þ normotensives, matched by gender, age (within 1 year), body mass index (BMI) (within 1 kg m À2 ) and smoking habit (no smoker, former smoker, current smoker) with HIV þ hypertensives.
Among the 320 never-treated patients referred to our outpatients' hypertension clinic during the same period, using the above listed criteria, we consecutively enrolled 30 HIVÀ hypertensive patients, matched by gender, age (within 1 year), BMI (within 1 kg m À2 ), smoking habit and mean 24 h systolic and diastolic BP values (within 3 mm Hg) with HIV þ hypertensive patients. From the hospital staff, we enrolled 30 HIVÀ normotensive subjects, matched by gender, age (within 1 year), BMI (within 1 kg m À2 ), smoking habit and mean 24 h systolic and diastolic BP values (within 3 mm Hg) with HIV þ normotensive patients.
The study was approved by the Ethical Committee of the Ospedale di Circolo and all the patients gave their informed consent.
All the subjects underwent: noninvasive 24-h ambulatory BP monitoring, LV echocardiographic examination and blood tests for fasting plasma glucose, fasting plasma insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides. Low-density lipoprotein (LDL) cholesterol was estimated from the Friedewald equation. 25 Homeostatic model assessment (HOMA) index was used to estimate insulin resistance. The unit was set to take readings every 15 min throughout the 24 h. We evaluated mean 24-h, daytime (from 0700 h to 1000 h) and night-time (from 1000 h to 0700 h) systolic and diastolic blood pressure and heart rate.
Echocardiographic examination
The echocardiographic examination was performed using an Agilent Sonos 5500 with a 2.0/2. 5 MHz transducer. LV M-mode echocardiograms were recorded under 2-dimensional control, at a paper speed of 100 mm sec À1 , with a simultaneous electrocardiogram. Tracings were evaluated by a single operator, unaware of the patients' characteristics. Considering 4 consecutive cardiac cycles of each echocardiogram, the following parameters were measured: LV end-diastolic diameter, end-diastolic thickness of interventricular septum, end-diastolic thickness of LV posterior wall, relative wall thickness (sum of posterior wall and septal thickness divided by LV end-diastolic diameter), LV mass 28 and LV ejection fraction. LV mass was normalized by height to the 2.7 power. 29 Mitral inflow velocities were evaluated by pulsedwave Doppler with the sample volume placed at the tips of mitral leaflets, from the apical 4-chamber view. Using the average of 5 beats, we measured the ratio between peak early transmitral flow velocity (E) and peak late transmitral flow velocity (A) (E/A ratio) and the deceleration time of E velocity (DT, time from peak E velocity to the time when E wave descent intercepted the zero line).
The pulsed tissue Doppler imaging (TDI) examination was performed from the apical 4-chamber view, with the sample volume placed along the myocardial lateral wall and along the left side of the interventricular septum, 1 cm above the mitral annulus. Using the average of 5 beats, we measured the septal and myocardial lateral wall early-diastolic velocities (E' and Em) and end-diastolic velocities (A' and Am) and their ratios (E'/A' and Em/Am).
LV hypertrophy was diagnosed when LVM index was 444 g m À2.7 in women, 448 g m À2.7 in men; 30 LV diastolic dysfunction was diagnosed when at least 3 of the followings were present: E/A o1, Em/Am o1, E'/A' o1, E wave Deceleration time 4200 msec or o150 msec.
Statistical analysis
Data are expressed as mean ± s.d. for continuous variables and percentages for categorical variables.
We compared mean values of all the parameters among the 4 groups by means of 2 (between HIV þ and HIVÀ subjects ) by 2 (between hypertensive and normotensive subjects) analysis of variance (ANO-VA), followed by the test of Scheffé. Chi-square test was used to compare proportions for categorical variables. A two-tailed Po0.05 was considered statistically significant.
Results
As a consequence of selection criteria, the 4 groups were comparable with regard to age, gender (26 men and 4 women in each group), BMI and prevalence of smoking habit (21 current smokers and 9 former smokers in each group) ( Table 1 ). The prevalence of positive family history of hypertension (one or both parents with hypertension) was also not significantly different among the 4 groups ( Mean values of fasting glucose, total cholesterol, HDL cholesterol and LDL cholesterol were similar among the 4 groups, whereas triglycerides and HOMA index were significantly higher in the 2 HIV þ groups ( Table 1 ). The prevalence of metabolic syndrome was higher in the 60 HIV þ patients than in the 60 HIVÀ subjects (19 patients, 31.6%, vs 7 patients, 11.6%, P ¼ 0.015).
By design, mean 24-h BP values were similar between HIV þ and HIVÀ normotensives and between HIV þ and HIVÀ hypertensives ( Table 2) ; moreover hypertension was never treated and its known duration was p6 months in all the hypertensive patients. Heart rate values were not different between the 4 groups throughout the 24 h (Table 2) .
With regard to LV characteristics, LV end-diastolic diameter was normal in all (o5.6 cm) and similar among the 4 groups ( Table 3) . Mean values of septal thickness, posterior wall thickness, relative wall thickness and LV mass index increased significantly from HIVÀ normotensives to HIVÀ hypertensives and HIV þ normotensives,who showed similar mean values to HIV þ hypertensives ( Table 3 ). The prevalence of LV hypertrophy (see 'Echocardiographic examination') was higher in HIV þ than in HIVÀ patients (24 patients, 40%, vs 9 patients, 15%, P ¼ 0.004). In particular the prevalence was greater in HIV þ hypertensives (17 patients, 56.6%) than in HIV þ normotensives (7 patients, 23.3%) and HIVÀ hypertensives (9 patients, 30%), whereas no HIVÀ normotensive subject had LV hypertrophy. LV ejection fraction was normal (X55%) 30 in all the 
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patients and similar among the 4 groups (Table 3) . Considering LV diastolic function, mean values of E/ A, Em/Am and E'/A' ratios were higher and E wave deceleration time lower in HIVÀ normotensives, whereas mean values of all the parameters were not significantly different among the other 3 groups (Table 3 ). The prevalence of preclinical LV diastolic dysfunction (see 'Echocardiographic examination') was higher in HIV þ than in HIVÀ patients (18 patients, 30%, vs 6 patients, 10%, P ¼ 0.012): the prevalence was greater in HIV þ hypertensives (13 patients, 43.3%) than in HIV þ normotensives (5 patients, 16.6%) and HIVÀ hypertensives (6 patients, 20%); no HIVÀ normotensive subjects had diastolic dysfunction. ANOVA (2 Â 2 factors) showed a significant effect of both HIV infection and hypertension on LV remodelling.
Discussion
From our results, asymptomatic HIV þ infection under chronic HAART is associated per se with myocardial hypertrophy and preclinical diastolic dysfunction not only in hypertensive patients, but also in patients with normal BP. Designing this study we used restrictive enrolment criteria in order to avoid relevant sources of potential bias. First, we selected subjects never treated with antihypertensive drugs or statins, in order to avoid the possible influence of these treatments LV characteristics and metabolic profile. [31] [32] [33] [34] Second, we matched the 4 groups by age, sex and BMI, all factors known to influence LV characteristics; moreover, we matched HIV þ and HIVÀ subjects also by smoking habit, since smoking 
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influences BP values, can increase insulin resistance and abdominal fat accumulation and seems also able per se to influence LV mass. 35, 36 Third, taking into account that the duration of hypertension and the degree of BP load influence LV remodelling, we enrolled only patients with newly diagnosed (p6 months) hypertension and we matched HIV þ and HIVÀ patients by 24-h BP values. Fourth, all the HIV þ patients had to be on stable HAART for at least 12 months before the enrolment, in order to avoid possible acute effects of treatment on metabolic, BP and LV parameters.
With regards to the methods employed, at odds with all the previous studies on HIV þ patients, we assessed BP values using 24-h ambulatory monitoring instead of few clinic measurements, in order to obtain a more reliable evaluation of BP profile. Moreover, we used different 24-h BP cut-off values for the diagnosis of normal (o125/80 mm Hg) 37 and high BP (X130 and/or 85 mm Hg), aiming to enrol well differentiated groups of normotensive and hypertensive subjects. Finally, taking into account that LV diastolic function is a complex phenomenon, for its evaluation we did not rely on a single method, as in previous studies on HIV patients that mainly used Doppler evaluation of transmitral flow, but we employed indices derived from Doppler transmitral flow (E/A ratio, deceleration time of E wave) and from Tissue Doppler Imaging (E'/A' and Em/Am ratios), diagnosing preclinical diastolic dysfunction when at least 3 parameters were abnormal (see 'Echocardiographic examination').
Compared to HIVÀ hypertensives, HIV þ hypertensives showed higher LV mass, due to greater septal and posterior wall thickness, with a more concentric pattern and a greater prevalence of LV hypertrophy. Although mean values of diastolic parameters were not significantly different between HIV þ and HIVÀ hypertensives, the prevalence of LV diastolic dysfunction was higher in HIV þ hypertensives. The differences in LV characteristics among the 2 groups were not accounted for by differences in age, gender, BMI, smoking habit or 24-h BP values, therefore it appears reasonable to conclude that the greater extent of LV remodelling in HIV þ hypertensives can be explained by HIV infection and/or chronic HAART per se.
The second relevant finding of our study comes from the comparison between HIV þ normotensive patients and the 2 HIVÀ groups. Despite superimposable 24-h BP values, HIV þ normotensives had greater LV mass and lower diastolic indices than HIVÀ normotensives; moreover HIV þ normotensives showed mean values of LV mass index and diastolic indices as well as prevalence of LV hypertrophy and diastolic dysfunction similar to HIVÀ hypertensives, whose 24-h BP values were significantly higher. This result, in our opinion, strengthens the hypothesis that HIV infection and/or chronic HAART concur to the development of LV remodelling, independently of BP profile. LV ejection fraction, index of systolic function, was normal in all the HIV þ subjects and similar among the 4 groups.
Our findings of increased LV mass, preclinical diastolic impairment and normal systolic function in HIV þ patients are partly in agreement with some, but not all the previous studies. [17] [18] [19] [20] [21] [22] [23] [24] In fact, taken together these studies obtained dissimilar results: if preclinical diastolic dysfunction is often reported, LV mass has been found increased, normal or even reduced and LV systolic function normal or, in few studies, impaired. 38 Actually, these studies can hardly be compared with each other and with our study, mainly because of great differences in such relevant issues as methods employed (that is, clinic BP values, absolute values of LV mass instead of values indexed for body surface area or height ) and patients characteristics (asymptomatic HIV þ patients, HIV þ patients with various degrees of malnutrition, AIDS patients, mixed groups of asymptomatic and symptomatic HIV þ patients, only women, only African or African-American subjects). Moreover in some studies HIV þ patients and controls were significantly different with regard to smoking habit, BMI and/or BP values; often no information was available about BP profile or antihypertensive and antidyslipidemic treatment. [17] [18] [19] [20] [21] [22] [23] [24] It is beyond the scope of this cross-sectional study to deal with the pathophysiologic mechanisms linking HIV infection and chronic HAART to LV remodelling. However, we can hypothesized that, besides other mechanisms like myocardial viral infection, direct myocardial mitochondrial toxicity by antiviral drugs and chronic inflammation, a relevant role could be played by metabolic complications. 3, 4, 38 We actually found, in agreement with the data from the literature, 3, 4, 11 that HIV þ patients had higher insulin resistance, defined by higher HOMA index, and greater prevalence of metabolic syndrome than HIVÀ subjects. As reported above, [13] [14] [15] [16] in subjects without HIV infection insulin resistance and metabolic syndrome have been linked per se to LV hypertrophy and diastolic dysfunction, through multiple mechanisms which are still not completely elucidated, including increased sympathetic activity, trophic effects of insulin on cardiomyocytes, chronic subclinical inflammation, activation of renin-angiotensin-aldosterone system; all these mechanisms are as well potential causes of myocardial hypertrophy and increased interstitial and perivascular fibrosis. 15, 39 The main limitation of our study is the lack of naive HIV þ patients. The very small number of naive subjects examined at our clinic prevented us from selecting such a group as to be consistent with the others. Therefore we can not distinguish between the role played by HIV infection per se and that played by HAART per se in influencing LV characteristics. A second limitation comes from the number of HIV þ subjects enrolled which is too small to subdivide them on the basis of the drugs employed, preventing us from analysing possible differences in drugs' effects on LV characteristics. Finally, 87% of the subjects examined were men, therefore our results may not be applicable to women.
Taken together, our findings point towards the conclusion that HIV infection and chronic HAART are associated per se with a greater remodelling in hypertensive patients and with the development of LV hypertrophy and diastolic dysfunction also in patients with normal BP. The metabolic changes associated with HIV infection and chronic HAART may play a significant role in the development of LV remodelling that increases per se the cardiovascular risk.
